Efficacy of Xuebijing injection in the treatment of post-interventional Syndrome of primary liver cancer and its effects on liver function and serum CRP, TNF-AND VEGF levels

doi:10.3877/cma.j.issn.2095-5782.2022.01.005

Abstract

Abstract:

Objective

To investigate the efficacy of Xuebijing injection on hepatic function and serum c-reactive protein (CRP) , tumor necrosis Factor-alpha (TNF-α) and Vascular endothelial growth factor in patients with primary hepatic Carcinoma (PHC) after interventional therapy.

Methods

A total of 102 patients with PHC Post-intervention Syndrome were randomly divided into two groups, 51 cases in each group.Two groups were given conventional treatment, observation group combined with Xuebijing injection treatment. The efficacy and safety of the two groups were compared. The changes of TCM syndrome total score, liver function index [aspartate transaminase, alanine transaminase, total Bilirubin (TBIL)], the levels of serum CRP, TNF-α and VEGF were compared between the two groups before and after treatment.

Results

The total effective rate of the observation group was 80.39%, which was significantly higher than that of the control group (56.86%)(P < 0.05). The total score of TCM Syndrome in both groups decreased significantly (P < 0.05) on the 3rd and 7th days after operation, and the decrease was more significant in the observation group (P < 0.05). The duration of pain, fever, nausea, vomiting and diarrhea in the observation group was significantly shorter than that in the control group (P < 0.05). The levels of serum ALT, AST, TBIL, CRP and TNF-α in the two groups were significantly increased 3 d after the operation compared with those before operation (P < 0.05), and significantly decreased 7 d after the operation compared with those 3 d after the operation (P < 0.05) The serum levels of ALT, AST, TBIL, CRP and TNF-α in the observation group were significantly lower than those in the control group at the same time point (P < 0.05). The levels of serum VEGF in the two groups were increased significantly after the operation (P < 0.05). However, the serum VEGF level in observation group was significantly lower than that in control group 7 days after operation (P < 0.05). There was no obvious adverse reaction in all subjects.

Conclusions

Xuebijing injection can effectively inhibit the expression of serum inflammatory factors and VEGF and alleviate liver injury in patients with PHC post-interventional syndrome.

Key words: Xuebijing injection, Post-interventional Syndrome of primary liver cancer, Liver function, Inflammatory reaction, Vascular endothelial growth factor

Hui Li, Haixia Li, Xiuxiang Wang. Efficacy of Xuebijing injection in the treatment of post-interventional Syndrome of primary liver cancer and its effects on liver function and serum CRP, TNF-AND VEGF levels[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(01): 27-31.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2022.01.005

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I01/27

Figures/Tables 6

References 17

[1]	万赤丹, 王国斌. 原发性肝癌治疗进展[J]. 腹部外科, 2019, 32(1): 1-6, 22.
[2]	Koya S, Kawaguchi T, Hashida R, et al. Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization[J]. J Gastroenterol Hepatol, 2019, 34(3): 580-588.
[3]	Shiozawa S, Usui T, Kuhara K, et al. Significance of transcatheter arterial chemoembolization for BCLC stage B hepatocellular carcinoma with mal-nutrition[J]. Gan To Kagaku Ryoho, 2018, 45(2): 350-352.
[4]	余静芳, 周晓玲, 陈峭, 等. 麻黄升麻汤治疗乙肝相关性原发性肝癌TACE术后栓塞综合征的疗效观察[J]. 辽宁中医药大学学报, 2018, 20(3): 136-139.
[5]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292.
[6]	中华人民共和国卫生部政司. 中国常见恶性肿瘤诊治规范第二分册原发性肝癌[M]. 北京: 北京医科大学中国协和医科大学联合出版社, 1991: 2-54.
[7]	国家中医药管理局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 156.
[8]	Kuwaki K, Nouso K, Miyashita M, et al. The efficacy and safety of steroids for preventing postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma [J]. Acta medica Okayama, 2019, 73(4): 333-339.
[9]	何伟, 赵许亚, 李俊祥, 等. 肝癌介入治疗对原发性肝癌中晚期患者的效果及肝功能的影响[J]. 实用临床医药杂志, 2017, 21(3): 71-74.
[10]	龚辉, 唐建清, 陈州华, 等. 柴芍六君子汤防治肝癌TACE术后栓塞综合征的临床研究[J].中医药导报, 2018, 24(22): 36-38.
[11]	闫春江, 黎永琳, 李燕, 等. 血必净注射液对脓毒症患者血清miR-223及高迁移率族蛋白B1表达的影响[J]. 疑难病杂志, 2019, 18(3): 243-246.
[12]	李娟, 林志芳. 异甘草酸镁对原发性肝癌肝动脉化疗栓塞术后炎症反应的影响及肝损伤的保护作用[J]. 中国现代普通外科进展, 2020, 23(3): 228-230.
[13]	马世堂, 俞浩, 张孝林, 等. 血必净组方药效物质基础与脓毒症多靶点作用效应研究[J]. 中国中西医结合杂志, 2015, 35(11): 1351-1355.
[14]	孙梦杰, 屠亚茹, 欧阳慧子, 等. 血必净注射液及其药代标示物对脓毒症大鼠炎性因子TNF-α, IL-1, IL-6, IL-8和IL-10表达的影响[J]. 天津中医药大学学报, 2018, 37(1): 13-15.
[15]	Liu X, Hu Z, Zhou B, et al. Chinese herbal preparation Xuebijing potently inhibits inflammasome activation in hepatocytes and ameliorates mouse liver ischemia-reperfusion injury[J]. PLoS One, 2015, 10(7): e131436.
[16]	刘俊, 武金才, 郑进方, 等.中晚期肝癌介入治疗后应用血必净的临床疗效观察[J]. 海南医学, 2018, 29(3): 413-415.
[17]	常旭, 张林, 孙鹏, 等. 右肾包膜动脉化疗栓塞在原发性肝癌介入治疗中的安全性及有效性研究[J]. 中华介入放射学电子杂志, 2020, 8(2): 135-140.

组别	例数	性别（例）		年龄（岁）	肝功能Child-Pugh分级		BCLC分期
组别	例数	男	女	年龄（岁）	A级	B级	B期	C期
观察组	51	29	22	58.24 ± 7.02	42	9	36	15
对照组	51	31	20	57.17 ± 6.83	44	7	39	12
χ²/t值		0.162		0.780	0.297		0.453
P值		0.687		0.437	0.586		0.501

组别	例数	性别（例）		年龄（岁）	肝功能Child-Pugh分级		BCLC分期
组别	例数	男	女	年龄（岁）	A级	B级	B期	C期
观察组	51	29	22	58.24 ± 7.02	42	9	36	15
对照组	51	31	20	57.17 ± 6.83	44	7	39	12
χ²/t值		0.162		0.780	0.297		0.453
P值		0.687		0.437	0.586		0.501

组别	例数	显效	有效	无效	总有效率
观察组	51	24	17	10	41（80.39）
对照组	51	15	14	22	29（56.86）
χ²值					6.557
P值					0.010

组别	例数	显效	有效	无效	总有效率
观察组	51	24	17	10	41（80.39）
对照组	51	15	14	22	29（56.86）
χ²值					6.557
P值					0.010

组别	例数	术后1 d	术后3 d	术后7 d
观察组	51	24.25 ± 5.76	17.23 ± 4.04^a	10.23 ± 2.45^ab
对照组	51	23.08 ± 6.22	20.34 ± 4.93^a	15.01 ± 3.12^ab
t值		0.986	3.485	8.605
P值		0.327	0.001	0.000

Please choose a citation manager

Content to export